Amicus Therapeutics Inc


Prices are adjusted according to historical splits.

Amicus Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$3.20 billion
Book Value:
Revenue TTM:
$336.79 million
Operating Margin TTM:
Gross Profit TTM:
$290.63 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Amicus Therapeutics Inc had its IPO on 2007-05-31 under the ticker symbol FOLD.

The company operates in the Healthcare sector and Biotechnology industry. Amicus Therapeutics Inc has a staff strength of 484 employees.

Stock update

Shares of Amicus Therapeutics Inc opened at $11.48 at the start of the last trading session i.e. 2023-06-02.

The stocks traded within a range of $11.4 - $12.2, and closed at $12.17.

This is a +6.85% increase from the previous day's closing price.

A total volume of 2,366,665 shares were traded at the close of the day’s session.

In the last one week, shares of Amicus Therapeutics Inc have increased by +3.93%.

Amicus Therapeutics Inc's Key Ratios

Amicus Therapeutics Inc has a market cap of $3.20 billion, indicating a price to book ratio of 24.7746 and a price to sales ratio of 10.5064.

In the last 12-months Amicus Therapeutics Inc’s revenue was $336.79 million with a gross profit of $290.63 million and an EBITDA of $-166712000. The EBITDA ratio measures Amicus Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Amicus Therapeutics Inc’s operating margin was -51.04% while its return on assets stood at -14.07% with a return of equity of -119.72%.

In Q1, Amicus Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 9.6%.

Amicus Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-0.7 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.18. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Amicus Therapeutics Inc’s profitability.

Amicus Therapeutics Inc stock is trading at a EV to sales ratio of 10.4563 and a EV to EBITDA ratio of -15.9064. Its price to sales ratio in the trailing 12-months stood at 10.5064.

Amicus Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$700.52 million
Total Liabilities
$138.39 million
Operating Cash Flow
$36.26 million
Capital Expenditure
$1.94 million
Dividend Payout Ratio

Amicus Therapeutics Inc ended 2023 with $700.52 million in total assets and $0 in total liabilities. Its intangible assets were valued at $700.52 million while shareholder equity stood at $102.57 million.

Amicus Therapeutics Inc ended 2023 with $5.91 million in deferred long-term liabilities, $138.39 million in other current liabilities, 2820000.00 in common stock, $-2585422000.00 in retained earnings and $197.80 million in goodwill. Its cash balance stood at $160.60 million and cash and short-term investments were $267.11 million. The company’s total short-term debt was $8,005,000 while long-term debt stood at $392.66 million.

Amicus Therapeutics Inc’s total current assets stands at $399.70 million while long-term investments were $0 and short-term investments were $106.51 million. Its net receivables were $68.18 million compared to accounts payable of $24.97 million and inventory worth $27.00 million.

In 2023, Amicus Therapeutics Inc's operating cash flow was $36.26 million while its capital expenditure stood at $1.94 million.

Comparatively, Amicus Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Amicus Therapeutics Inc stock is currently trading at $12.17 per share. It touched a 52-week high of $13.84 and a 52-week low of $13.84. Analysts tracking the stock have a 12-month average target price of $15.8.

Its 50-day moving average was $11.46 and 200-day moving average was $11.63 The short ratio stood at 7.99 indicating a short percent outstanding of 0%.

Around 86.1% of the company’s stock are held by insiders while 10576.8% are held by institutions.

Frequently Asked Questions About Amicus Therapeutics Inc

The stock symbol (also called stock or share ticker) of Amicus Therapeutics Inc is FOLD

The IPO of Amicus Therapeutics Inc took place on 2007-05-31

Similar Industry Stocks (Biotechnology)

Last Price
Jyothy Labs Limited (JYOTHYLAB)

Most Active

Last Price
Zomato Limited (ZOMATO)
Tesla Inc (TSLA)
Yes Bank Limited (YESBANK)

Top Gainers

Last Price
AEye Inc (LIDRW)

Top Losers

Last Price


Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children’s Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.


3675 Market Street, Philadelphia, PA, United States, 19104